How to Choose a Custom Synthesis CRO: The Buyer's Evaluation Guide

Why Choosing the Wrong Synthesis Partner Costs More Than the Contract

The most expensive number in a custom synthesis decision is rarely on the proposal. It is the cost of switching vendors after a failed campaign, plus the cost of timeline slip, plus the cost of route re-optimization at the next vendor who has to start over. Procurement teams who treat custom synthesis like a commodity purchase consistently spend more in total program cost than teams who run a structured vendor evaluation up front. This is not a hypothetical — it is the recurring pattern in retrospective reviews of biotech and pharma R&D budgets.

Route Re-optimization Costs at Scale

When a CRO that ran a 10-g lot cannot scale the same chemistry to 1 kg, the next vendor inherits the SOPs but not the tacit knowledge — and ends up redoing process development to hit the new scale. That is typically a $200K to $800K rework that the original RFP would have caught with a simple “show me a campaign you took from gram to kilogram on a similar scaffold” question. The milligram-to-multi-ton custom synthesis playbook walks through which CRO capabilities actually scale across decades and which break.

Timeline Penalties When a CRO Can’t Deliver

Timeline slip in custom synthesis cascades into clinical timeline slip, which cascades into financing risk for a venture-backed biotech. A vendor that delivers four weeks late on a critical intermediate can push a Phase 1 IND filing by a quarter — six to eight weeks for the chemistry to recover, plus the regulatory queue impact, plus a missed development milestone. For a Series A biotech burning $1M per month, four weeks of late delivery can translate to $1M of unproductive runway. Vendor selection is not a procurement-margin decision. It is a runway-management decision.

Photo: Vitaly Gariev / Unsplash

The Six Capabilities That Actually Matter

Every custom synthesis CRO will claim every capability. The evaluation work is verifying which of those claims is operational versus marketing. These six categories, each with a discrete proof point, separate credible vendors from optimistic ones.

1. Complexity Range: Novel Scaffolds vs. Catalog Chemistry

Some CROs are excellent at making catalog quantities of well-known intermediates, but lose efficiency on novel scaffolds where the route is not in the literature. Others are deep in route-development chemistry but expensive for the simple stuff. Specify which side of the line your project sits on, and ask the CRO to show you a comparable molecule they have synthesized de novo. A ten-step route through new chemistry is a different capability from a three-step route through a published procedure. CROs that cannot produce the prior-art molecule on request usually cannot do the chemistry.

2. Scale Flexibility: Milligram to Kilogram Without a New Vendor

The most expensive vendor switch happens at the milligram-to-gram or gram-to-kilogram transition, where one CRO that did the early-stage chemistry hands off to a different one for the scale-up. The receiving CRO has to redevelop the route to fit their suite, their analytical platforms, and their procurement supply chain. A vendor that can take the same molecule from 1 g to 1 kg to 50 kg without a route redesign saves the program months. Confirm by asking for a case study where the same vendor scaled the same scaffold across at least two orders of magnitude.

3. Regulatory Credentials: cGMP, FDA-Registered, or Non-GMP?

Match the regulatory class to the molecule’s intended use. A discovery intermediate going into a 30-day rat tox study does not need cGMP, but a Phase 1 clinical lot does. The mismatch goes both ways — buying GMP material at GMP price for a non-GMP need wastes 30-60% of the chemistry budget, and buying non-GMP material when GMP is needed leaves the program with a clinical hold risk. The GMP vs non-GMP decision framework covers exactly which regulatory class fits which use case. Ask the CRO for their FDA registration number, their last inspection date, and any open Form 483 observations.

4. Analytical Integration: In-House Characterization vs. Third-Party

Vendors who outsource analytical characterization to a third party introduce a coordination cost and a documentation gap that compounds across the campaign. In-house qNMR, HPLC-MS, GC-headspace, ICP-MS, chiral HPLC, and XRPD let the chemistry team make release decisions in the same building, with a single chain of custody. For Phase 1 clinical work, in-house analytical method development and ICH-grade release services are essentially mandatory. For early-discovery catalog work, third-party analytical is acceptable but adds a week of cycle time per batch.

5. IP Protection Protocols and NDAs

Confirm before any structure leaves your office: the CRO’s NDA terms, their internal compartmentalization model (which scientists see what), their use of independent project codes, and their policy on retained samples. Some CROs file patent applications on their own scaffolds and need to be walled off from your structure space. Most reputable CROs are transparent about this — but you have to ask. A CRO that is vague about IP protocols at the proposal stage is going to be vague about it during the campaign.

6. Communication and Project Management Model

The single biggest predictor of on-time delivery is whether the CRO assigns a named project manager with chemistry training. Account managers without chemistry depth cannot escalate technical issues fast enough. Look for: weekly status calls with a written agenda, a single accountable PM, direct chemist-to-chemist contact when needed, and a change-control process that flags scope changes before they consume budget. Vendors who hide their chemists behind sales staff are vendors who deliver late.

Photo: Vitaly Gariev / Unsplash

Weighted Scoring Matrix: How to Rank Competing Proposals

A scoring matrix turns three apparently-similar proposals into a ranked list with a defensible decision trail. Adjust the weights to match the project — early-discovery catalog work weights complexity and IP lower, while IND-enabling work weights regulatory and analytical higher.

Capability	Weight	Vendor A	Vendor B	Vendor C
Complexity / route-development depth	20%	8	6	9
Scale flexibility (mg → kg)	15%	7	9	6
Regulatory credentials (GMP / FDA reg)	20%	9	5	8
Analytical integration	15%	8	7	9
IP and NDA protocols	10%	9	8	7
Communication / PM model	15%	7	9	8
Quoted price and timeline credibility	5%	6	9	7
Weighted total	100%	7.85	7.20	7.95

A few rules for using the matrix:

• Score on a 1-10 scale where 1 is “no evidence” and 10 is “documented case study with verifiable references”
• Have two evaluators score independently, then reconcile — single-evaluator scores skew toward sales-team rapport
• Treat any score below 5 in a category weighted 15%+ as a disqualifier, not a deficit
• If two vendors score within 0.5 points, the deciding factor should be a real reference call, not the matrix

The matrix is a tool for organizing judgment, not for replacing it. Two evaluators who score independently and reconcile will land on a defensible decision the procurement committee can sign off on.

What to Include in Your Synthesis RFP (Template)

A well-structured RFP gets back proposals you can actually compare. A bad RFP gets back proposals where every vendor scopes a different deliverable, and the procurement team spends a week normalizing them.

Section 1 — Project Overview

• Target molecule (structure file: mol or SMILES, plus IUPAC name)
• Stage of program (discovery, lead optimization, IND-enabling, commercial)
• Intended use (in vitro, in vivo, GLP tox, GMP clinical, commercial)
• Required scale (with delivery date for each scale)
• Required purity and characterization

Section 2 — Technical Specifications

• Route preferences or constraints (avoidance of specific reagents, IP-restricted chemistry)
• Critical impurity controls (named impurities, limits)
• Solid-form requirements if any (specific polymorph, salt form)
• Chiral specifications if applicable (ee target, method)

Section 3 — Regulatory and Quality

• Required GMP/non-GMP classification
• Documentation deliverables (CoA, batch record, CMC narrative)
• Stability program scope if any
• ICH coverage required (Q3A, Q3C, Q3D)

Section 4 — Commercial Terms

• Pricing format requested (fixed-price, time-and-materials, hybrid)
• Milestone schedule and payment terms
• Material ownership and IP terms
• Termination conditions

Section 5 — Vendor Qualifications

• Two case studies of comparable molecules
• FDA registration status and last inspection outcome
• Named project manager and team CVs
• Three customer references for similar projects

A 12-page RFP filled correctly returns better proposals than a 30-page legal-form RFP filled by procurement boilerplate. Keep it specific.

Questions to Ask During the Technical Review Call

The technical review call is where you separate vendors who can do the chemistry from vendors who quoted on it. Eight questions that surface real capability:

1. Walk me through the proposed route, step by step, with the rationale for each disconnection
2. What’s the riskiest step in the route, and what’s your contingency plan if it fails?
3. Show me a process development report you delivered for a similar molecule
4. Who is the named PhD chemist running this program, and how many similar campaigns have they led?
5. What’s your expected yield envelope for the limiting step, and what’s your historical first-pass yield on similar chemistry?
6. How will you characterize the major impurities, and what’s your impurity ID timeline?
7. If we hit a quality issue on delivery, what’s the deviation investigation process and timeline?
8. What’s your scale-up plan from this lot to the next campaign — same suite, same chemists, same SOPs?

Vendors who answer these crisply have run the chemistry before. Vendors who hedge or generalize are pricing the work without having scoped it. The process chemistry path from lab to pilot gives a deeper read on what good answers to questions 1, 5, and 8 actually sound like.

Warning Signs in a Proposal or Initial Quote

Six patterns to flag during proposal review. Any one is a yellow flag; two or more is a deal-breaker.

• Generic route description. A serious proposal includes a numbered scheme with named reagents and conditions, not a paragraph saying “standard medicinal chemistry transformations will be used”
• No named PM with chemistry training. Account managers as the single point of contact predict slipped timelines
• Pricing identical from gram to kilogram on a per-gram basis. Real chemistry economics are non-linear with scale; a flat per-gram quote means the CRO has not modeled the campaign
• No FDA registration data on file when GMP is in scope. Either the CRO is not FDA-registered, or they are not used to clients asking — both are issues
• NDA boilerplate with one-way IP terms favoring the vendor. Reasonable CROs use balanced NDAs; aggressive IP terms in the NDA preview the contract terms
• Case studies that cannot be verified by reference. Vendors who cannot produce two reachable customer references for similar work either do not have the experience or have burned the references

If a vendor shows three or more of these signs, no amount of price discount makes them the right choice. Walk away — the other two proposals on the table will deliver more value at higher quoted price.

Photo: National Cancer Institute / Unsplash

How ChemContract Research Approaches Evaluation Conversations

ChemContract Research has been on both sides of the RFP table for 25+ years. We have synthesized 7,000+ products across 60+ R&D and manufacturing facilities, supported by 500+ scientists across discovery, process chemistry, GMP manufacturing, and analytical development. When a prospective client opens an evaluation conversation with us, our default is to make verification easy:

• Named PhD project chemist assigned at the proposal stage, not after PO
• Two case study writeups matched to your scaffold class, with structures and yields at gram, kilo, and pilot scales
• FDA registration data and last inspection outcome shared at NDA execution
• In-house analytical platforms — qNMR, HPLC-MS, GC-headspace, ICP-MS, chiral HPLC/SFC, XRPD, DSC/TGA — visible in the proposal
• Reference call slots with three customers for similar work, available on request
• Tiered scale pricing that reflects real chemistry economics, not flat per-gram rates

For pharmaceutical industry programs and venture-backed biotechs, this transparency is the baseline. Quote turnaround is 24 hours. Standard evaluation conversations from first call to executable proposal run two weeks.

If you are mid-vendor-evaluation and want a comparable proposal that scores cleanly against your matrix, request a quote with structure file, scale, intended use, and target ship date. We will return a fit-for-purpose proposal inside one business day.

Frequently Asked Questions

1. How long should custom synthesis vendor evaluation take? Two to four weeks from RFP send to PO. Faster decisions skip critical due diligence; slower ones lose the candidate vendor’s program calendar slot. A two-week structured evaluation with three competing proposals returns the best outcomes for most projects.

2. Should we always pick the lowest-cost custom synthesis CRO? No. The cheapest proposal almost always omits process development, impurity work, or analytical method qualification — costs the sponsor absorbs later. Total program cost is what matters, not the headline price on the proposal. A 15-20% premium for a verified-capable vendor pays back in saved timeline and reduced rework.

3. How do we verify a CRO’s claimed capabilities? Request two case studies of similar molecules with structure-level detail, three customer references for comparable work, and the team CV of the proposed project chemist. Take the reference calls — half an hour each — before signing.

4. What’s the most important capability for IND-enabling chemistry? Process chemistry depth combined with FDA-inspected GMP capacity in the same organization. The handoff between development chemistry and GMP manufacturing is where most IND timelines slip; vendors who run both in-house compress the critical path.

5. Do we need GMP for early-discovery custom synthesis? Generally no. Discovery intermediates and most preclinical material can be manufactured non-GMP at significant cost savings, then transitioned to GMP for IND-enabling work. The right CRO will offer both classes and recommend the right one for each stage.

6. How important is the named project manager? Critical. The named PM with chemistry training is the strongest single predictor of on-time delivery. Account managers without chemistry depth cannot escalate technical issues fast enough; vendors who refuse to name the PM at the proposal stage are revealing their internal staffing model.

7. What contract terms should we negotiate hardest on? Material ownership, IP terms, deviation handling and credit policy, and termination clauses. Pricing is rarely the highest-leverage negotiation point — contractual terms governing what happens when the campaign goes sideways usually have higher dollar impact than the headline price.